The endocannabinoid system consists of lipid signaling molecules called endocannabinoids, principally anandamide and 2-arachidonoylglycerol, along with their G-protein-coupled receptors, CB1 and CB2, and the enzymes that synthesize and degrade these messengers. CB1 receptors are abundant on nociceptive sensory neurons in the dorsal root ganglia, where their activation dampens the release of pain-transmitting neurotransmitters. CB2 receptors are found predominantly on immune cells, including mast cells and macrophages, and their engagement suppresses the release of proinflammatory cytokines. Beyond these classic receptors, cannabinoids also interact with non-cannabinoid targets such as the ion channel TRPV1, the nuclear receptor PPAR-gamma, serotonin receptors, and orphan G-protein-coupled receptors like GPR18 and GPR55, giving the system an unusually broad pharmacological reach.

What makes this system particularly relevant to endometriosis is that it is not merely a bystander. Human studies have documented elevated systemic levels of endocannabinoids and related mediators across the menstrual cycle in women with endometriosis, and cannabinoid receptor expression has been detected directly in endometriotic lesions. Animal work has shown that the CB1 receptor contributes to the development of ectopic lesions in a mouse model of the disease, while other studies report decreased expression of cannabinoid receptors in the eutopic and ectopic endometrium of patients with adenomyosis, a closely related condition. In other words, the endocannabinoid machinery appears to be rewired in diseased tissue, positioning it as both a marker and a potential driver of pathology.

The review organizes the therapeutic logic of cannabinoids around three mechanistic pillars: inflammation, nociceptive signaling, and lesion proliferation. On the inflammatory front, endometriosis is characterized by a peritoneal environment awash with proinflammatory cytokines, activated macrophages, and degranulating mast cells, all of which sensitize nearby nerve fibers. Cannabinoids attenuate this cascade by inhibiting proinflammatory cytokine signaling and reducing the release of inflammatory mediators from mast cells and peritoneal macrophages. Cannabidiol, the non-psychoactive phytocannabinoid, has been shown in molecular studies to blunt the inflammatory and oxidative processes associated with endometriosis, and CB2-selective agonists reduce cytokine release in blood mononuclear cells. Because neurogenic inflammation, driven by mast cells and nerve fiber interactions, is increasingly recognized as central to endometriosis pain, this immunomodulatory action is a plausible route to symptom control.

The second pillar concerns direct suppression of pain signaling and sensitization. Endometriosis-associated pain involves peripheral, central, and cross-sensitization, in which repeated nociceptive input from pelvic lesions amplifies responses throughout the nervous system, sometimes producing comorbid pain syndromes such as fibromyalgia. Cannabinoids counter this at multiple levels. Activation of peripheral CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception, and genetic studies indicate that cannabinoid analgesia is mediated largely through peripheral type 1 cannabinoid receptors on nociceptors. Cannabidiol acts on TRPV1 signaling pathways in cultured dorsal root ganglion neurons, and CB1 receptor agonists can prevent nerve growth factor-induced sensitization of TRPV1 in sensory neurons, a mechanism directly relevant to the elevated TRPV1 expression observed in the dorsal root ganglia of rats with endometriosis and in peritoneal endometriotic foci of women with chronic pelvic pain.

The third pillar is antiproliferative. Endometriotic lesions behave somewhat like benign tumors, proliferating, invading, and recruiting new blood vessels. Synthetic cannabinoid agonists such as WIN 55212-2 have been shown to target proliferation, angiogenesis, and apoptosis via MAPK/AKT signaling in human endometriotic cell lines and in a murine model of the disease. Cannabinoid agonists exert antiproliferative effects on deep infiltrating endometriosis tissue, and cannabidiol demonstrated anti-inflammatory, antioxidative, and antiangiogenic effects in an experimental rat model. Natural delta-9-tetrahydrocannabinol has even shown disease-modifying effects on endometriosis-associated pain in animal studies, suggesting that cannabinoids might not only mask symptoms but also slow lesion growth, a property that no current medical therapy can claim.

The mechanistic enthusiasm is mirrored by striking epidemiological reality. Surveys from Australia, New Zealand, Canada, Germany, and the United States consistently show that large numbers of women with endometriosis are already using cannabis, often illicitly or without medical supervision, to self-manage their pain, and many report perceived effectiveness. A national survey of Australian women identified cannabis as a common self-management strategy, and international cross-sectional research conducted during the COVID-19 pandemic documented continued and in some cases increased use. National survey data further indicate substantial willingness among women to try cannabis for gynecological conditions. This grassroots adoption has outpaced the clinical evidence, creating a situation in which patients are experimenting on themselves with products of variable composition and dosing, while physicians lack the trial data needed to guide them.

The review’s authors argue that this gap makes properly controlled clinical trials an urgent priority. Several challenges stand in the way. Cannabinoid pharmacology is complicated by the entourage effect, in which combinations of phytocannabinoids and terpenes may produce effects different from isolated compounds, and by the psychoactivity of THC, which limits tolerable doses. However, recent structural and pharmacological advances are opening new doors. The discovery of a cryptic pocket in the CB1 receptor that drives peripheral and functional selectivity suggests it may be possible to design analgesics that activate pain-relieving pathways without central psychoactive effects. Separately, the sodium channel Nav1.8 has been identified as an analgesic target for non-psychotomimetic phytocannabinoids, offering another route to pain relief without intoxication. Such advances could yield peripherally restricted cannabinoid medicines tailored to endometriosis, an approach that would sidestep many of the regulatory and tolerability obstacles that have hampered the field.

There is also an opioid angle that gives the research public-health urgency. Women with endometriosis are frequently prescribed opioids for their pain, and cohort studies in US administrative claims data have documented chronic opioid use and its complication risks in this population. Cannabinoids interact with the opioid system, and a growing body of preclinical and clinical evidence supports an opioid-sparing effect of cannabinoids for analgesia. Because cannabinoid receptor expression has been detected in endometriotic lesions of women with the disease, some researchers have proposed cannabinoid-based approaches as an alternative to opioid-based pain medication. If clinical trials confirm meaningful analgesia, cannabinoids could help reduce opioid exposure in a patient population disproportionately affected by long-term opioid therapy and its attendant risks of dependence and hyperalgesia.

Cautious optimism is the appropriate stance. The evidence base remains dominated by in vitro studies and animal models, and human interventional data are still sparse, while the endocannabinoid system also plays fundamental roles in endometrial and placental biology, raising questions about reproductive safety that trials must address. Yet the convergence of epidemiological demand, mechanistic plausibility across inflammation, nociception, and proliferation, and emerging medicinal chemistry that promises non-psychoactive, peripherally targeted drugs makes the endocannabinoid system one of the most compelling therapeutic frontiers in endometriosis research. As the Wayne State team concludes, the system’s regulation of nociception, inflammation, and lesion growth warrants rigorous clinical evaluation, and for the millions of women whose pain has outlasted every existing therapy, that evaluation cannot come soon enough.

Subject of Research: The role of the endocannabinoid system in the mechanisms and treatment of endometriosis-associated pain

Article Title: The Endocannabinoid System in Endometriosis-Associated Pain: Mechanisms, Molecular Targets, and Therapeutic Implications

Article References: Stone, A. M., Veltre, V. L., Camp, O. G., Biernat, M. M., & Abu-Soud, H. M. (2026). The Endocannabinoid System in Endometriosis-Associated Pain: Mechanisms, Molecular Targets, and Therapeutic Implications. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02201-9

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02201-9

Keywords: endometriosis, endocannabinoid system, cannabinoids, cannabidiol, chronic pelvic pain, CB1 receptor, CB2 receptor, inflammation, nociception, TRPV1, lesion proliferation, clinical trials

The research team, led by Jonathan Mokhtar of Mohammed Bin Rashid University of Medicine and Health Sciences and colleagues at institutions including Case Western Reserve University and the Cleveland Clinic, mined the TriNetX Research Network, a federated database of de-identified electronic health records drawn from more than 100 healthcare organizations. From an initial pool of 31,288 adults who underwent infraumbilical panniculectomy between January 2010 and April 2025, the investigators identified 801 patients with an ICD-10 diagnosis of cannabis use disorder recorded within six months before surgery. After 1:1 propensity score matching on age, sex, race or ethnicity, body mass index, and comorbidities including diabetes, hypertension, chronic obstructive pulmonary disease, nicotine dependence, and alcohol use, 798 matched pairs remained for analysis.

Propensity matching is the statistical workhorse that gives observational studies like this one their credibility. Because patients are not randomized to cannabis use, the researchers had to construct comparison groups that were as similar as possible in every measurable respect except the exposure of interest. They used greedy nearest-neighbor matching with a caliper of 0.2 standard deviations of the logit of the propensity score, and after matching, all covariates showed standardized differences below the conventional 0.1 threshold, indicating well-balanced cohorts. The matched population had a mean age of 43.2 years, was 80.3 percent female, and had a mean body mass index of 32.1, with comorbid conditions such as diabetes and nicotine dependence distributed almost identically between the two groups.

The headline result concerns pain. Patients with cannabis use disorder experienced clinically significant postprocedural pain at a rate of 14.0 percent, compared with 7.8 percent among controls—a risk ratio of 1.82, meaning an 82 percent relative increase in risk. Expressed another way, the absolute risk difference was 6.27 percentage points, yielding a number needed to harm of 16: for every 16 patients with cannabis use disorder undergoing the procedure, one additional case of significant postoperative pain could be expected. The authors defined postprocedural pain using diagnostic codes indicating pain severe enough to require documentation or intervention, not the routine discomfort expected after major abdominal surgery.

Wound-related outcomes told a similar story. Postprocedural skin complications, which included infections of the skin and subcutaneous tissue as well as conditions such as panniculitis and disorders of skin appendages, occurred in 10.0 percent of the cannabis use disorder cohort versus 6.8 percent of controls, corresponding to a risk ratio of 1.48. Secondary outcomes—hospital readmission, sepsis or gangrene, hematoma or seroma, venous thromboembolism, and pulmonary embolism—showed numerically higher rates in the cannabis group but did not reach statistical significance. A Kaplan-Meier time-to-event analysis found complication-free survival of 85.1 percent at 90 days in the cannabis group versus 87.6 percent in controls, a difference that did not achieve significance on log-rank testing.

Why might cannabis impair surgical recovery? The answer lies in the endocannabinoid system. Delta-9-tetrahydrocannabinol and cannabidiol act on CB1 and CB2 receptors to modulate immune responses, nociception, angiogenesis, inflammation, vascular tone, and hemostasis—all core elements of postoperative healing. Preclinical work summarized by the authors indicates that cannabinoids can impair platelet aggregation, delay fibroblast proliferation, disrupt angiogenesis, inhibit neutrophil chemotaxis, impair collagen synthesis, and interfere with re-epithelialization. In vitro studies have demonstrated anticoagulant effects, with THC suppressing thrombin-induced clot formation at measurable concentrations. Notably, these effects appear dose- and context-dependent: low-dose or topical cannabidiol may even have pro-reparative properties, while systemic or high-dose THC is consistently associated with delayed tissue regeneration.

The pain finding is particularly intriguing because it runs counter to cannabis’s popular reputation as an analgesic. Chronic cannabis users may develop altered nociceptive thresholds and cross-tolerance with opioids, potentially requiring modified pain regimens after surgery. Prior large database studies support this concern: cannabis users have been shown to report higher postoperative pain scores, greater opioid consumption, and increased postoperative nausea and vomiting. The new study also performed a stratified analysis by nicotine dependence, finding that the association between cannabis use disorder and postoperative pain persisted in both nicotine-dependent patients, where the risk ratio was 1.96, and non-nicotine-dependent patients, where it was 1.73. This consistency across subgroups suggests cannabis is an independent risk factor rather than a proxy for smoking-related harm, though the authors caution that overlapping pathophysiology between inhaled cannabis and nicotine makes fully disentangling their contributions difficult.

The study arrives at a moment of rapidly shifting context. As of June 2025, medical marijuana is legal in 40 U.S. states and recreational cannabis in 24, and more than half of Americans report having used marijuana at least once. Among adults aged 18 to 35—the demographic most likely to seek body-contouring procedures—past-year use approaches 30 percent. Meanwhile, product potency has climbed dramatically: the average THC content of cannabis in the European Union reached 24.8 percent in 2022, more than double that of traditional herbal cannabis, and higher potency is linked to greater dependence risk. Synthetic cannabinoids add a further, largely unquantified layer of perioperative risk, given their high-affinity binding to cannabinoid receptors and their association with cardiovascular and neurological toxicity.

The authors are candid about limitations. Reliance on ICD-10 coding captures only diagnosed cannabis use disorder—just 2.6 percent of the initial cohort, well below the general population prevalence—meaning the findings apply to patients with clinically recognized, likely more severe patterns of use and cannot be generalized to occasional or recreational users. The database provides no information on dose, frequency, route of administration, or formulation, and retrospective coding in a stigmatized area invites both under-reporting and misclassification. Panniculectomy, with its large soft-tissue envelope, high wound tension, and elevated baseline complication rate, is a sensitive model for detecting risk factors, but results may not translate to procedures with lower tissue demands.

Nevertheless, the clinical implications are actionable. The American Society of Regional Anesthesia and Pain Medicine has already issued consensus guidelines recommending routine preoperative cannabis screening, documentation of route and frequency, patient counseling, and consideration of abstinence for at least two weeks before elective procedures, particularly when cannabis is inhaled. Building on their findings, the study team proposes a five-step perioperative checklist: screen all patients and characterize route of administration; document frequency, dose, duration, and concurrent nicotine use; counsel on wound-healing and infection risks; recommend cessation two to four weeks before elective body contouring; and tailor analgesic plans to account for altered pain processing in chronic users. As cannabis use continues to normalize, the authors argue, incorporating such screening into preoperative risk assessment is no longer optional—it is an essential safeguard for procedures that place extraordinary demands on the body’s capacity to heal.

Subject of Research: The association between cannabis use disorder and postoperative complications after panniculectomy.

Article Title: Association of cannabis use disorder with postoperative complications following panniculectomy: a multicenter propensity-matched analysis

Article References: Mokhtar, J., Ha, J. Y., Almeida, V. F. A., Lellouch, A. G., Vyas, K. S., Doh, S. J., & Duraes, E. F. R. (2026). Association of cannabis use disorder with postoperative complications following panniculectomy: a multicenter propensity-matched analysis. BMC Plastic and Reconstructive Surgery, 2(1), Article 1. https://doi.org/10.1186/s44452-026-00013-z

Image Credits: AI Generated

DOI: 10.1186/s44452-026-00013-z

Keywords: cannabis use disorder, panniculectomy, postoperative complications, wound healing, propensity score matching, body contouring, cannabinoids, perioperative risk, plastic surgery, pain management, TriNetX, nicotine co-use

The study’s central observation concerns apoptosis, a form of programmed cell death that allows damaged or dangerous cells to dismantle themselves in a controlled manner. Unlike accidental cell rupture, apoptosis is governed by molecular circuits involving stress sensors, mitochondrial disruption, caspase enzymes and the eventual fragmentation of cellular components. Chemotherapy and radiotherapy are commonly effective against cancer partly because they activate these pathways. By damaging DNA, destabilizing cellular structures or generating excessive oxidative stress, these treatments can push tumor cells beyond their ability to recover.

Glioblastoma presents a particularly formidable biological challenge because its cells can adapt rapidly to hostile conditions. The tumor is highly heterogeneous, meaning that different groups of cells may carry distinct mutations and respond differently to treatment. It also infiltrates healthy brain tissue, making complete surgical removal difficult. Radiotherapy and chemotherapy therefore remain important components of management, but resistance frequently develops. Any molecular process that reduces treatment-induced apoptosis could allow a fraction of malignant cells to survive, recover and continue dividing.

Cannabinoids are a diverse group of chemical compounds that interact with cannabinoid receptors and related signaling systems. The best-known receptors, CB1 and CB2, are coupled to intracellular pathways that can influence neurotransmission, inflammation, metabolism, stress responses and cell survival. Cannabinoid signaling is complex: depending on the compound, concentration, receptor profile and cellular context, it has been associated with either pro-death or pro-survival effects. This context dependence is especially important in cancer biology, where a molecule that kills one tumor model may protect another from environmental or therapeutic stress.

The new report specifically connects cannabinoid exposure with reduced apoptosis after chemotherapy or ionizing radiation in glioblastoma cells. Ionizing radiation carries enough energy to remove electrons from atoms and molecules, producing direct DNA lesions as well as reactive oxygen species that intensify cellular damage. Chemotherapeutic agents can cause related stress through different mechanisms, including interference with DNA replication, disruption of cell division or formation of toxic molecular intermediates. If cannabinoid signaling dampens the downstream response to this damage, cells may avoid mitochondrial outer-membrane permeabilization, limit caspase activation or increase the expression of survival-associated pathways.

That possibility does not mean cannabinoids have a single, uniform effect on all cancers or that every cannabinoid product would behave in the same way. Cannabinoid preparations vary widely in their chemical composition, receptor activity, dose and route of administration. Laboratory concentrations can also differ substantially from levels reached in human tissues. The biological outcome may depend on whether a compound primarily activates CB1, CB2 or non-cannabinoid molecular targets, and on the genetic state of the glioblastoma cells being studied. These variables make it difficult to translate a cellular observation directly into a clinical recommendation.

The findings are nevertheless important because cannabinoids are increasingly present in conversations surrounding cancer treatment. Patients may use cannabis-derived products to manage pain, nausea, appetite changes, anxiety or sleep disturbances, sometimes while receiving radiation or cytotoxic drugs. Supportive care can be valuable, but the new research suggests that symptom management and tumor biology should not be considered completely separate issues. If cannabinoids interfere with treatment-induced apoptosis in certain settings, clinicians may need to know which compounds are being used, at what doses and during which phases of therapy.

The study also highlights the need for carefully designed follow-up research. Scientists will need to determine whether the observed suppression of apoptosis occurs consistently across patient-derived glioblastoma models, organoids or animal systems, and whether it affects tumor growth or treatment response in living organisms. Molecular experiments could identify the precise signaling nodes involved, including changes in mitochondrial integrity, caspase activity, DNA-damage responses and antioxidant defenses. Clinical investigations, if justified by preclinical evidence, would require rigorous monitoring of treatment outcomes, cannabinoid exposure and potential interactions with specific chemotherapy or radiotherapy regimens.

For now, the message is one of caution rather than alarm. The work does not establish that cannabinoids universally worsen glioblastoma or that patients should independently stop prescribed medications. Instead, it exposes a potentially significant biological interaction that deserves attention as cannabinoid use becomes more common. In a disease where treatment success depends on pushing cancer cells toward irreversible death, any compound capable of blunting that response could matter. The research by Picucci, Qin, Osman and colleagues therefore adds a striking layer of complexity to the debate over cannabinoids and cancer, showing that a substance viewed as helpful in one context may interfere with therapy in another.

Subject of Research: Cannabinoids and their effects on chemotherapy- and ionizing radiation-induced apoptosis in glioblastoma cells.

Article Title: Cannabinoids suppress chemotherapy- and ionizing radiation-induced apoptosis of glioblastoma cells.

Article References: Picucci, F., Qin, X., Osman, M. et al. “Cannabinoids suppress chemotherapy- and ionizing radiation-induced apoptosis of glioblastoma cells.” Cell Death Discovery (2026). https://doi.org/10.1038/s41420-026-03298-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03298-2

Keywords: Cannabinoids, glioblastoma, apoptosis, chemotherapy, ionizing radiation, cancer treatment, treatment resistance, cell survival.